Prospects for the use of hepatotropic LOLA therapy in veterinary practice

Abstract

Relevance. There are enough works devoted to the LOLA therapy in treatment ofhepatopathy of various origins, however, these works are devoted to research in medicine or in laboratory studies of animals.Methods. For inclusion in the experiment, screening studies of the blood plasma of horses for the level of gamma-glutamyltransferase were carried out. The inclusion criteria was the value of the activity of glutamyltransferase in blood serum more than 22 U/l (upper limit of the reference interval). As a result of screening studies, 20 animals for inclusion in the experiment were identified, which were divided into two parity groups. The second group received L-ornithine L-aspartate as hepatotropic therapy at a dosage of 0.05 g/kg of body weight orally (in the form of a powder, previously dissolved in water) once a day for 28 days.Results. On the 7th day of the experiment, the GGT level decreased by an average of 5.63% compared to the control, on the 14th day — by 12.45%, on the 21st day — by 15.95%, at the end of the experiment — by 20.09%. Beginning on day 14 of therapy the amount of GGT in the experimental group reached reference values.Clinical trial data support l the thesis that LOLA has hepatoprotective properties in cases of hepatopathy of various origins, which is proved by a decrease in the level of GGT in the blood serum. Larger studies with a variety of designs, as well as comparison with other organ-specific measures, are needed to confirm these initial results. Thus, the use of LOLA hepatotropic therapy in liver diseases receives a new justification for use in veterinary medicine.